PT  - JOURNAL ARTICLE
AU  - Philippe de Medina
AU  - Nadia Boubekeur
AU  - Patrick Balaguer
AU  - Gilles Favre
AU  - Sandrine Silvente-Poirot
AU  - Marc Poirot
TI  - The Prototypical Inhibitor of Cholesterol Esterification, Sah 58-035 [3-[Decyldimethylsilyl]-<em>N</em>-[2-(4-methylphenyl)-1-phenylethyl]propanamide], Is an Agonist of Estrogen Receptors
AID  - 10.1124/jpet.106.104349
DP  - 2006 Oct 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 139--149
VI  - 319
IP  - 1
4099  - http://jpet.aspetjournals.org/content/319/1/139.short
4100  - http://jpet.aspetjournals.org/content/319/1/139.full
SO  - J Pharmacol Exp Ther2006 Oct 01; 319
AB  - We have shown recently that estrogen receptor (ER) ligands share a diphenyl ethane pharmacophore with Sah 58-035 [3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]-propanamide], a prototypical inhibitor of the acyl-cholesterolacyl-transferase (ACAT), which enabled us to establish that ER ligands were potent inhibitors of ACAT and blocked the formation of foam cells. In the present study, we have tested whether this structural similarity means that Sah 58-035 is an ER modulator. We report that Sah 58-035 bound to ERα and ERβ with an IC50 of 2.9 and 3.1 μM, respectively. Docking studies using molecular modeling of Sah 58-035 with the X-ray structure of the ER showed that Sah 58-035 fits well into the ligand binding site known for 4-hydroxy-tamoxifen. Despite having high three-dimensional structural similarities with the pure antiestrogen ICI 164,384 [(N-n-butyl-N-methyl-11-[3,17β-di-hydroxyestra-1,3, 5(10)-trien-7α-yl]-undecanamide], we showed that Sah 58-035 is an agonist of ER for transcription and cellular proliferation. These data showed that Sah 58-035 was an estrogen receptor agonist and that the size and the chemical nature of the side chain were critical for agonist versus antagonist activity on ER. This new molecular mechanism of action for Sah 58-035 has to be taken into account in understanding better its pharmacological activities. Moreover, these data give new structural insights into the understanding of agonist versus antagonist activities of ER ligands and also for the conception of new drugs with a dual ACAT inhibition and ER modulation potential and their evaluation in different pathologies where both targets are involved, such as atherosclerosis, Alzheimer's disease, and cancer. The American Society for Pharmacology and Experimental Therapeutics